Commercializing early-stage technologies can be a high-risk venture where only about 10% cross the finish line.
From licensing to exit strategies, a panel of biotech startup founders, venture fund leaders, and university tech transfer will navigate and optimize this process for successful commercialization in Biotech and Big Pharma. We'll also address the most common pitfalls and how to avoid them.
Pricing: $49
Print Page
